GC Partners Increases Stake in SANIGEN to 54.06% via Third-Party Allocation at 31% Discount; Conversion Price Adjustment Adds Potential Dilution
GC Partners acquired 637,845 new shares of SANIGEN on July 6, 2026 through a third-party allocation rights offering at 1,411 KRW per share, representing a 31% discount to the market price of 2,050 KRW. This transaction dilutes existing shareholders.
The acquisition increased GC Partners' stake from 52.10% to 54.06%, with voting share ownership at 48.00%. Additionally, the conversion price of GC1ho's convertible bonds was adjusted from 2,190 KRW to 2,181 KRW, increasing potential conversion shares by 7,537.
The stated purpose is to exercise influence over management. The total acquisition cost of approximately 900 million KRW was funded from the company's cash holdings. GC Partners has a high debt-to-equity ratio of 387%, indicating financial risk.
[AI Summary]The major shareholder's participation in a discounted rights offering dilutes minority shareholders and clearly aims to consolidate control. Combined with the convertible bond adjustment, potential dilution may increase further, posing a negative outlook for the stock price. Investors should closely monitor additional fundraising and governance risks.